EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
NCT ID: NCT07020520
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2025-10-01
2031-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Optilume
Treatment with Optilume for ureteric stricture
Optilume
Has pre-treatment (balloon dilation or ureterotomy) followed by paclitaxel-coated balloon (Optilume) treatment of the ureteric stricture.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optilume
Has pre-treatment (balloon dilation or ureterotomy) followed by paclitaxel-coated balloon (Optilume) treatment of the ureteric stricture.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Single lesion ureteric or uretero-enteric stricture less than or equal to 4.0 cm in length
3. Two functioning kidneys
Exclusion Criteria
2. Subjects with more than one ureteric stricture
3. Subjects with target stricture in bifid or duplicated ureter
4. Known sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel
5. Ureteric stricture caused by extrinsic compression of the ureter
6. Unable to endoscopically access target stricture for any reason
7. Existing stones in the ipsilateral kidney or ureter (except for asymptomatic kidney stones) that are in close proximity to the target ureteric stricture
8. Chronic renal failure treated with dialysis
9. eGFR \<30 mL/min/1.73m2
10. Kidney function ≤ 25% of split function on the side with target stricture as measured by functional renogram
11. Kidney function ≤35% of split function on the side opposite target stricture as measured by functional renogram or other significant pathology or impairment that may impact renal function
12. Life expectancy less than 12 months
13. Women who are pregnant or breastfeeding
14. Women of child-bearing potential planning to get pregnant in the next year or are unwilling to use contraception over the next 12 months
15. Males unwilling to abstain or use protected sex for 30 days post treatment
16. Males unwilling to use highly effective contraception for6 months post treatment if sexual partner(s) are of child-bearing potential
17. Inability to provide legally effective informed consent
18. Unwilling or unable to meet protocol follow-up requirements
19. Participation in any interventional clinical investigation of a medical device, drug, or biologic (excluding registries) that may confound the results of the trial
20. Active systemic or urinary tract infection
21. Active malignancy in the abdomen or pelvis, or any malignancy considered considerable risk for metastasizing to the abdomen or pelvis over the next 12 months
22. Uncontrolled diabetes defined as hemoglobin A1C ≥ 8% at baseline
23. Unable to come off antiplatelet or anticoagulation medication prior to treatment to prevent bleeding complications at the discretion of the investigator
24. Any other condition that may confound the results of the trial or presents an unacceptable risk for any study-related procedure
25. Individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response
26. Presence of any condition that precludes administration of furosemide during renograms
27. Unable to tolerate contrast related to required study procedures or imaging.
Additional Criteria for Pharmacokinetic Substudy Inclusion Ureteric stricture measurements appropriate for treatment with a 6mm (18F) or 8mm (24F) diameter Optilume DCB Exclusion Prior treatment with any device or medical therapy that contains paclitaxel, including drug coated balloons for vascular and urethral applications
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laborie Medical Technologies Inc.
INDUSTRY
Urotronic Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jamie Landman, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Irvine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Irvine
Orange, California, United States
Orlando Health
Orlando, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Steven M Principal Clinical Project Manager
Role: CONTACT
Phone: 952-426-6079
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jaime Landman, MD
Role: primary
Lucas Wiegand, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1391
Identifier Type: -
Identifier Source: org_study_id